This is consistent with the findings of the IBIS-I breast cancer prevention trial follow-up which showed that patients were more likely to be ER and PR negative following tamoxifen usage, though this trial examined patients who were taking primary rather than secondary chemoprevention [16]. This evidence concerns the gene PGR and breast carcinoma.